wegovy (Credit: Canva)
People receiving weight-loss drug Wegovy sustained weight loss for up to four years, shedding an average of 10% of their body weight in that time, as per a new study. Wegrovy is a brand that markets semaglutide injections, that have gained widespread attention for their weight-loss effects. The study also found that Semaglutide injections boost an individual's heart health, even when weight loss doesn't take place.
The study, called SELECT, was published in journal Nature Medicine. "At four years, we see ongoing benefits of semaglutide," said Cheng-Han Chen, MD, interventional cardiologist from Cardiologist, who was not involved in the research. Besides the weight loss, it also lead to a loss in cardiovascular outcomes.
The research was conducted on 17000 adults, who had obesity but did not have diabetes. Overall, people who received once-weekly injections of semaglutide lost on average 10.2% of their body weight over the course of four years. All of the study participants continued to lose weight for about 65 weeks, a year and three months, and then their weight remained at a stable level.
Of the people on the highest dose of Wegovy, 68% lost at least 5% of their body weight. This compared to 21% of people on the placebo. Additionally, of the total people on Wegovy about 23% lost at least 15% of their body weight. For those in the placebo group, only 1.7% lost that much body weight.
Researchers found that even individuals who did not experience significant weight reduction while on the drug saw a reduced risk of major heart events. Recent analysis of the SELECT trial data revealed that semaglutide significantly lowers the risk of heart attack, stroke, and cardiovascular-related deaths in adults with obesity or those who are overweight. Notably, the results of this study lead the US FDA to approve Novo Nordisk's Wegovy for reducing heart-related risks in this group.
Semaglutide, marketed under the brand name Wegovy, is primarily an antidiabetic medication used to treat Type 2 diabetes. It is also an anti-obesity drug used for long-term weight management. While it can be taken as a subcutaneous injection or orally, it has significant side effects. It primarily impacts your gastrointestinal tract and its side effects include constipation, nausea, abdominal pain, diarrhoea, and fatigue amongst others.
Credit: AI Generated Image
Fatty liver disease has traditionally been associated with obesity and alcohol consumption. However, in clinical practice, we are increasingly seeing fatty liver in individuals who may not appear overweight and who do not consume alcohol. This changing pattern reflects a larger problem: the close relationship between liver health, metabolic health, and lifestyle.
Non-alcoholic fatty liver disease (NAFLD), now increasingly termed metabolic dysfunction-associated steatotic liver disease (MASLD), occurs when excess fat accumulates in the liver in association with metabolic risk factors. A systematic review and meta-analysis of Indian studies estimated the pooled prevalence of NAFLD among adults at 38.6%, meaning that roughly one in three adults may be affected. The prevalence was approximately 28.1% in average-risk populations and increased to 52.8% among individuals with higher metabolic risk.
What is particularly important for Indians is that fatty liver cannot be identified simply by looking at body weight. South Asian populations can develop visceral or abdominal fat and metabolic abnormalities even at relatively lower body mass indices. A South Asian meta-analysis found that NAFLD affected approximately 26.9% of adults in the general population, while prevalence rose to 54.1% among people with metabolic diseases. Importantly, around 43.4% of people with NAFLD in the analysis were not obese.
Diabetes, hypertension, dyslipidaemia, central obesity and metabolic syndrome are therefore important warning signs. In my practice, I often emphasise that a normal-looking body does not necessarily mean a metabolically healthy body. Waist circumference, blood sugar, lipid profile, liver enzymes, and, when indicated, liver imaging provide a much more meaningful risk assessment.
The other misconception is that fatty liver is harmless. Simple steatosis may remain stable in many individuals, but some patients develop inflammation and progressive fibrosis, eventually leading to cirrhosis and liver cancer. A systematic review of hepatocellular carcinoma in India also found that the proportion of cases associated with NAFLD has been increasing, although viral hepatitis remains an important cause. ([PubMed][3])
There is also a broader gastroenterological concern. Digestive and liver health are closely connected with dietary patterns, physical activity, and metabolic health. Excessive intake of refined carbohydrates, sugary beverages, ultra-processed foods, and excessive calories, combined with inadequate physical activity, can contribute to metabolic dysfunction.
The good news is that lifestyle modification can make a substantial difference in fatty liver. Weight reduction, regular physical activity, improved dietary quality, adequate sleep, and better control of diabetes and cholesterol can help reduce liver fat and metabolic risk. Importantly, management should be individualised rather than based on crash diets or unregulated supplements.
Fatty liver should therefore be viewed not merely as an incidental finding on an ultrasound report, but as a metabolic warning signal. Early identification allows us to intervene before irreversible liver damage develops. For patients, the message is simple: taking care of the liver also means taking care of the heart, metabolism, and overall digestive health.
The statistics cited above are based on published systematic reviews/meta-analyses and IARC/WHO data; prevalence estimates vary depending on the population and diagnostic method.
Dr. Pradipta Kr. Sethy, Director Gastroenterology, Manipal Hospitals EM Bypass & Mukundupur
Credit: iStock
Endometriosis is a chronic disease affecting about 1 in 10 women worldwide. Diagnosis and treatment remain challenging, particularly for women with severe pain and other complications.
Now, US researchers have developed a targeted nanotherapy that showed promising results against endometriosis in early testing.
Scientists at Washington State University found that the treatment reduced endometriosis lesions, symptoms and pain sensitivity after a single dose in mice.
The findings were published in Advanced Healthcare Materials. Researchers hope to eventually test the treatment in humans.
Also read: Endometriosis Can Take Years To Diagnose But This AI Tool Can Identify Its Signs In 18 Milliseconds
The drug, niclosamide, was previously used to treat intestinal tapeworm infections in humans and is still used in animals.
Earlier research found that niclosamide could reduce endometriosis lesions and inflammation. However, it is not suitable for long-term use, limiting its potential as a treatment for a chronic condition.
To overcome this, researchers developed a nanotherapy that delivers niclosamide directly to cells associated with endometriosis.
“We found the disease-specific immune cell, and then we had a drug, but we couldn’t target the cell with the drug alone,” said Kanako Hayashi, professor at WSU’s School of Molecular Biosciences.
“So we used this nanocarrier that delivers the drug specifically to the disease site,” Hayashi said.
The team used a nanosized molecule called a dendrimer to bind with niclosamide and deliver it in a more soluble form.
In mice, a single injection reduced the size and number of lesions and lowered pain sensitivity.
“Although we still need to clear multiple phases, this study is telling us the efficacy is strong, and this nanocarrier is stable, so far, for two weeks—and we think we can go longer,” Hayashi said.
If the treatment remains stable for longer periods, researchers believe it could potentially be given less frequently. Hayashi said a monthly injection could be possible in the future, but this would depend on further testing.
READ: Endometriosis Taught Me To Always Listen To My Body, Says Model Padma Lakshmi
Not yet. The treatment has only been tested in mice and must undergo further safety and efficacy testing before human trials.
Researchers also do not yet know whether it would ultimately be given as an injection or IV infusion.
Endometriosis affects an estimated 190 million women worldwide. It occurs when tissue similar to the lining of the uterus grows outside the uterus.
It can cause severe pelvic pain, painful periods, pain during sex and infertility. Symptoms are sometimes dismissed as a “bad period,” contributing to delays in diagnosis.
There is currently no cure, although treatments can help manage symptoms.
Treatment depends on symptoms, disease severity and fertility goals.
Hormonal medicines can help control pain and disease activity but may cause side effects and can affect fertility while being used.
Painkillers, including non-steroidal anti-inflammatory drugs, may help manage discomfort.
Laparoscopic surgery can remove lesions and endometriotic cysts and may help restore pelvic anatomy. It can also improve fertility in some women, although the disease can recur.
Lifestyle measures such as regular exercise, stress management and dietary changes may also support symptom management.
Credit: iStock
Lung development of the fetus depends on the physical and genetic health of the parents.
At birth, breathing begins with air from the environment, containing oxygen and other gases, and is influenced by known and unknown forces of nature. The air then passes through well-developed nostrils, which regulate the air temperature and prevent foreign bodies from entering the body and help protect against diseases.
Breath travels through the nasal passages, sinuses, pharynx (throat), larynx (voice box), trachea (breathing tubes), bronchi, small airways, air sacs, interstitial membrane, into thin-walled blood vessels that transport oxygen and collect gases and other substances to be expelled from the body.
The diaphragm, the muscle that separates the lungs from the abdomen, is the most powerful breathing apparatus.
The lungs in the early stages of life undergo dramatic changes from newborn→ infancy→ childhood→ puberty→ teenage→ adults→ middle age→ seniors. Factors influencing lung health risks keep changing with age, depending on genetics, environment & external factors.
The lungs and airways perform non-respiratory functions of protecting the body against harmful insults, both from within and external threats, and it also protects against insults received from other organs of the body. The lungs have a powerful defense mechanism protecting the body and also have hormonal, physical, and immunological defense mechanisms.
© $2026 Times Horizon Private Limited